Shown is the binding partner CRIPT (yellow) in the active site with the blue-to-red colour gradient indicating increasing potential for allosteric effects. Based on PDB accession 1BE9.

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses ...

“Our internal pipeline has been enabled by our ability to identify novel, functional allosteric binding pockets that allow us to rapidly progress novel chemical matter. We look forward to ...

Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats ...